NCT07137247

Brief Summary

The purpose of this observational study is to follow up on chronic HBV-infected patients over a long period of time to understand the changes in the immune status as age increases and the natural history of chronic HBV infection progresses. The main questions it aims to answer are:

  • Does the natural history of chronic HBV infection progress with changes in HBV-specific immunity?
  • What is the role of age in the natural history of chronic HBV infection? Patients with chronic HBV infection who are untreated and aged 1-80 years will be followed up every six months. During each follow-up, HBV-related serological and virological indicators will be tested. Peripheral blood samples will also be collected to test HBV-specific immunity and the immune environment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
189mo left

Started Feb 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Feb 2024Dec 2041

Study Start

First participant enrolled

February 1, 2024

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 19, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 22, 2025

Completed
15.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2040

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2041

Last Updated

September 30, 2025

Status Verified

September 1, 2025

Enrollment Period

16.8 years

First QC Date

June 19, 2025

Last Update Submit

September 28, 2025

Conditions

Keywords

HBVChronic Hep BHBV infection

Outcome Measures

Primary Outcomes (1)

  • In accordance with the 2018 AASLD Hepatitis B guidelines, the natural history of HBV is staged based on the laboratory test results (HBV serological markers, viral load, and liver function) and imaging findings of the enrolled patients.

    Enrolled patients will undergo examinations of HBV serological markers, viral load, liver function, liver ultrasound, and liver fibrosis every six months. Subsequently, based on the 2018 AASLD Hepatitis B guidelines , patients will be staged to observe whether there are changes in the natural history of hepatitis B.

    over a follow-up period of 5 years

Secondary Outcomes (1)

  • The HBV-specific immune response levels will be measured using the immune cells of the enrolled patients

    over a follow-up period of five years

Study Arms (1)

Chronic hepatitis B virus (HBV) infection

Patients with chronic HBV infection who are untreated and aged 1-80 years. Follow-ups will be conducted every six months, with a minimum of six visit points.

Procedure: Venipuncture

Interventions

VenipuncturePROCEDURE

For adults (including those who are 18 years old): During the routine follow-up visits, an extra 30 milliliters of peripheral blood will be drawn. For minors (under 18 years old): During the routine follow-up visits, an extra 6 milliliters of peripheral blood will be drawn. Follow-ups will be conducted every six months, with a minimum of six visit points.

Chronic hepatitis B virus (HBV) infection

Eligibility Criteria

Age1 Year - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population consists of chronic hepatitis B patients who have not received antiviral therapy within the past six months.

You may qualify if:

  • Aged 1-80 years, either male or female.
  • Patients diagnosed with chronic hepatitis B virus infection in accordance with the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B" (2019 edition).
  • No antiviral treatment (including nucleoside analogs and interferons, etc.) within the past six months.

You may not qualify if:

  • Other Unsuitable Conditions:

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China

RECRUITING

MeSH Terms

Conditions

Hepatitis BHepatitis B, Chronic

Interventions

Phlebotomy

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepadnaviridae InfectionsDNA Virus InfectionsVirus DiseasesHepatitis, Viral, HumanHepatitisLiver DiseasesDigestive System DiseasesHepatitis, ChronicChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Blood Specimen CollectionSpecimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesTherapeuticsSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2025

First Posted

August 22, 2025

Study Start

February 1, 2024

Primary Completion (Estimated)

December 1, 2040

Study Completion (Estimated)

December 1, 2041

Last Updated

September 30, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations